The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus

Pediatrics. 2009 Dec;124(6):1676-9. doi: 10.1542/peds.2009-2346.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / economics
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Cross-Sectional Studies
  • Evidence-Based Medicine*
  • Health Care Costs / statistics & numerical data
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature, Diseases / economics
  • Infant, Premature, Diseases / immunology
  • Infant, Premature, Diseases / prevention & control*
  • Palivizumab
  • Population Surveillance
  • Practice Guidelines as Topic
  • Respiratory Syncytial Virus Infections / diagnosis
  • Respiratory Syncytial Virus Infections / economics
  • Respiratory Syncytial Virus Infections / immunology*
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Viruses / drug effects*
  • Respiratory Syncytial Viruses / immunology*
  • Risk Factors
  • United States

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab